Aventis Pharmaceuticals Inc.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Genzyme Corporation

Rorer Pharmaceutical Corporation

Mark Czekaj

Scott I Klein

Bruce F Molino

Charles J Gardner

Julian Roy Levell

John L Kane, Jr

Yong Mi Choi-Sledeski

Markus Metz

Gregory Bernard Poli

Andrew Scholte

Alan Collis

Michael Kothe

Jinyu Liu

Jeffrey C Pelletier

Liang Ma

Roy J Vaz

Barret Giese

Paul Erdman

Claude Barberis

Tieu-Binh Le

Linli Wei

Vinod Francis Patel

Heinz W Pauls

Kent W Neuenschwander

Peter Charles Astles

Michael R Becker

Yong Gong

Guyan Liang

Olivier Houille

Paul R Eastwood

Heinz Pauls

James R Pribish

Jeffrey M Dener

Patrick Wai-Kwok Shum

Patrick Shum

Alan John Collis

Compounds of the formula or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. The compounds are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R, P, Pand Pare as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.

Substituted propane phosphinic acid derivatives

This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa

Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

Chemical compounds

The invention is directed to a non-hygroscopic stable crystalline form of the antithrombotic compound N-�N-�N-(4-piperdin-4-yl)butanoyl)-N-ethylglycyl!-(L)-aspartyl!-(L)-.beta. -cyclohexyl-alanine amide, to processes for preparing said stable crystalline form, to a pharmaceutical composition thereof, and intermediates thereof, and the invention is directed also to processes for preparing a compound of the formula ##STR1## wherein: A, B, Z, E.sup.1, E.sup.2, G, R, m, n, and p are as defined herein.

Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides

This invention relates to novel peptide and pseudopeptide derivatives and analogs of aspartic acid which are useful as inhibitors of platelet aggregation and thrombus formation in mammalian blood, to pharmaceutical compositions including such compounds, and to their use in inhibiting thrombus formation and platelet aggregation in mammals.

Antithrombotic peptides and pseudopeptides

Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof containing certain amino acids and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Anti-thrombotic peptides and pseudopeptides

Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Growing community of inventors

Doylestown, PA, United States of America

Mark Czekaj